Nuvation Bio CEO Buys 500,000 Shares in $893,500 Insider Purchase

David Hung, President, CEO, Director, and 10% owner of Nuvation Bio (NUVB), has made a significant insider purchase of 500,000 shares of Class A Common Stock on June 16, 2025.

Rhea-AI Filing Summary

David Hung, President, CEO, Director, and 10% owner of Nuvation Bio (NUVB), has made a significant insider purchase of 500,000 shares of Class A Common Stock on June 16, 2025. The shares were acquired at a weighted-average price of $1.787 per share, with purchase prices ranging from $1.64 to $1.88.

Following this transaction, Hung's direct ownership increased to 59,281,054 shares. The substantial purchase by the company's chief executive, representing an investment of approximately $893,500, may signal management's confidence in the company's future prospects.

Key transaction details:

• Transaction type: Direct purchase of common stock
• Total transaction value: ~$893,500
• Filing was signed by Stephen Dang as attorney-in-fact
• No derivative securities were involved in this transaction

Positive

• CEO David Hung purchased 500,000 shares at ~$1.79 per share, representing a significant $893,500 open market purchase showing strong insider confidence
• The CEO maintains a substantial position of over 59.2 million shares, demonstrating long-term commitment to the company

Negative

• None.

Insider Trade Summary

Net Buyer: 500,000 shares

Net Buy 1 txn

Insider Hung David

Role PRESIDENT AND CEO

Bought 500,000 shs ($894K)

Type	Security	Shares	Price	Value
Purchase	Class A Common Stock	500,000	$1.787	$894K

Holdings After Transaction: Class A Common Stock — 59,281,054 shares (Direct)

Footnotes (1)

1. F1. ) The price reported is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.64 to $1.88, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

FAQ

How many shares of NUVB stock did CEO David Hung purchase on June 16, 2025?

According to the Form 4 filing, CEO David Hung purchased 500,000 shares of NUVB Class A Common Stock on June 16, 2025.

What was the purchase price for NUVB shares in CEO David Hung's recent insider transaction?

The shares were purchased at a weighted-average price of $1.787 per share, with the actual purchase prices ranging from $1.64 to $1.88 per share.

How many NUVB shares does David Hung own after his June 2025 purchase?

Following the reported transaction, David Hung directly owns 59,281,054 shares of Nuvation Bio Inc. (NUVB) Class A Common Stock.

What positions does David Hung hold at NUVB according to the Form 4?

According to the Form 4, David Hung serves as President and CEO of Nuvation Bio Inc. He is also a Director and a 10% Owner of the company.

When was NUVB's Form 4 insider trading report filed with the SEC?

The Form 4 was filed with the SEC on June 28, 2025, reporting a transaction that occurred on June 16, 2025. The form was signed by Stephen Dang as Attorney-in-Fact on June 18, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2025 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hung David

(Last) (First) (Middle)

C/O NUVATION BIO INC.

1500 BROADWAY, SUITE 1401

(Street)

NEW YORK NY 10036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuvation Bio Inc. [ NUVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND CEO

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/16/2025		P		500,000	A	$1.787(1)	59,281,054	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. ) The price reported is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.64 to $1.88, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

	/s/ Stephen Dang, Attorney-in-Fact	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.